- ISPOR-FDA Summit 2020
- ISPOR 2020
- ISPOR Asia Pacific 2020
- ISPOR Dubai 2020
ISPOR Europe 2020
- ISPOR Europe 2019
- ISPOR Summit 2019
- ISPOR Latin America Summit 2019
- ISPOR Latin America 2019
- ISPOR 2019
- ISPOR Warsaw 2019
- ISPOR Europe 2018
- ISPOR Summit 2018
- ISPOR Dubai 2018
- ISPOR Asia Pacific 2018
- ISPOR 2018
- ISPOR Europe 2017
- ISPOR Latin America 2017
- ISPOR Asia Pacific 2016
- Abstract Information
- Submit Abstract
- Exhibits & Sponsorships
- Awards & Grants
- Recent Conferences
- Upcoming Conferences
Education & Training
- In-Person Training
- Introduction to Outcomes Research
- Introduction to Systematic Reviews & Meta-Analysis
- Systematic Review & Meta-Analysis: Applications
- Introduction to Pharmacoeconomics
- Cost-of-Illness/Cost-Estimation (COI/CE)
- Cost-Minimization/Cost-Consequence (CMA/CCA)
- Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA)
- Modeling Health Care Costs – Part I: Characteristics of Health Care Costs
- Modeling Health Care Costs – Part II: Methods and Guidelines for Estimating Health Care Costs
- Modeling Health Care Costs – Part III: Estimation from Censored Data
- Introduction to Budget Impact Analysis (BIA) - Part I
- Introduction to Budget Impact Analysis (BIA) - Part II
- Markov Model Toolkit: Concepts, Assumptions and Examples
- An Introduction to Choice-Based Conjoint Analysis (Discrete Choice Experiments)
- Health-Related Quality of Life (HRQOL) – Basics
- Patient Reported Outcomes: Analysis and Interpretation
- Patient Reported Outcomes: Instrument Development
- Item Response Theory: A Conceptual Introduction
- Preparing for Multinational Clinical Trials: Translation and Cultural Adaptations of PRO Measures
- Evidence Generation for Patient Reported Outcome (PRO) Label Claims (FDA Requirements)
- Intermediate Retrospective Observational Study - Propensity Scoring Methods
- Use of Public Survey Data in Health Outcomes Research
- Distance Learning
This module is an introduction to the role of cost-consequence (CC)/cost-minimization analysis(CMA) in medical decision making from multiple perspectives. It will describe situations in which CCA/CMA is the acceptable method of pharmacoeconomic (PE) analysis, the components included, computational methods, the concept of efficacy vs. effectiveness and establishing equivalent outcomes.
By the end of the Cost-Minimization/Cost-Consequence (CMA/CCA) module, you will be able to:
- State the role of cost-consequence (CC)/cost-minimization analysis (CMA) in medical decision making.
- Contrast the price of a drug product and the cost of drug therapy.
- Define the components of CC/CMA.
- Understand the computations involved in CC/CMA.
- Understand the concerns in attribution of cost components to a particular treatment arm.
- Summarize the resources used in a therapy or service and assign monetary values to those resources.
- Analyze the value for money from health technologies.
- Summarize how CC/CMA are used in health policy decisions regarding government approval of and reimbursement for therapies.
- Use and apply sensitivity analyses and discounting techniques in CC/CMA.
- Explain how point of view and perspective affect CC/CMA.